Chronic myeloid leukemia--advances in biology and new approaches to treatment.

By J. Goldman, J. Melo. New England Journal of Medicine, 2003

982 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/70654fbfecbcb9eb41b5a7f8b0880bc7422a7cd0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Hematology

Citations in the corpus

The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. (2015, background): “Imatinib (STI571) Imatinib, approved by the Food and Drug Administration in 2001, is a first generation BCR-ABL inhibitor that inhibits proliferation of myeloid cells containing the BCR-ABL oncogene and is used in patients with chronic myeloid leukemia (CML) (Goldman and Melo, 2003; Stegmeier et al.”
Mechanisms and insights into drug resistance in cancer (2013, positive): “Such strategies include (i) inhibition of a specific oncoprotein, such as targeting the oncogenic fusion proteins Bcr–Abl and PML–RARA with Gleevec and all trans retinoic acid (ATRA) with arsenic trioxide respectively or (ii) activation of a specific immune response against cancerous cells demonstra”
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. (2005, background): “The fact that (1) the mutation was present at a level substantially less than the wild-type allele in many heterozygous cases, (2) the wild-type allele was detectable in the great majority of homozygous patients, and (3) the age of homozygous cases (median, 63 years; range, 17-69 years) was not sign”
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (2010, background): “adelphia [Ph] chromosome), which carries a unique fusion gene, termed BCR-ABL1.(1) In the absence of”
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, background): “ubsequently, it was realized that a durable response to imatinib as only seen in CML-CP patients [21,37].”